ORIC PHARMACEUTICALS, INC. Operating Cash Flow
ORIC PHARMACEUTICALS, INC. (ORIC) reported Operating Cash Flow of -$64.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-03
- ORIC PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$31.61M.
- ORIC PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$32.44M.
- ORIC PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$22.48M.
- ORIC PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$25.11M.
- ORIC PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$110.97M.
- ORIC PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$112.66M.
- ORIC PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$85.69M.
- ORIC PHARMACEUTICALS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$75.14M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$31.61M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$64.04M 10-Q · filed 2026-08-03 | -$86.53M derived: sum of 3 quarters · filed 2026-08-03 | -$111.64M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$32.44M 10-Q · filed 2026-05-04 | -$54.92M derived: sum of 2 quarters · filed 2026-05-04 | -$80.03M derived: sum of 3 quarters · filed 2026-05-04 | -$110.88M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$22.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$47.59M derived: sum of 2 quarters · filed 2026-02-23 | -$78.44M derived: sum of 3 quarters · filed 2026-08-03 | -$110.97M 10-K · filed 2026-02-23 |
| 2025-09-30 | -$25.11M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$55.95M derived: sum of 2 quarters · filed 2026-08-03 | -$88.49M 10-Q · filed 2025-11-13 | -$116.54M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | -$30.84M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$63.38M 10-Q · filed 2026-08-03 | -$91.43M derived: sum of 3 quarters · filed 2026-08-03 | -$120.23M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | -$32.53M 10-Q · filed 2026-05-04 | -$60.59M derived: sum of 2 quarters · filed 2026-05-04 | -$89.38M derived: sum of 3 quarters · filed 2026-05-04 | -$115.01M derived: sum of 4 quarters · filed 2026-05-04 |
| 2024-12-31 | -$28.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$56.85M derived: sum of 2 quarters · filed 2026-02-23 | -$82.48M derived: sum of 3 quarters · filed 2026-02-23 | -$112.66M 10-K · filed 2026-02-23 |
| 2024-09-30 | -$28.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$54.42M derived: sum of 2 quarters · filed 2025-11-13 | -$84.61M 10-Q · filed 2025-11-13 | -$108.88M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | -$25.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$55.81M 10-Q · filed 2025-08-12 | -$80.08M derived: sum of 3 quarters · filed 2025-08-12 | -$99.73M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$30.19M 10-Q · filed 2025-05-05 | -$54.46M derived: sum of 2 quarters · filed 2025-05-05 | -$74.10M derived: sum of 3 quarters · filed 2025-05-05 | -$95.25M derived: sum of 4 quarters · filed 2025-05-05 |
| 2023-12-31 | -$24.27M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-18 | -$43.91M derived: sum of 2 quarters · filed 2025-02-18 | -$65.06M derived: sum of 3 quarters · filed 2025-02-18 | -$85.69M 10-K · filed 2025-02-18 |
| 2023-09-30 | -$19.64M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$40.79M derived: sum of 2 quarters · filed 2024-11-12 | -$61.42M 10-Q · filed 2024-11-12 | -$76.75M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$21.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$41.77M 10-Q · filed 2024-08-12 | -$57.10M derived: sum of 3 quarters · filed 2024-08-12 | -$76.42M derived: sum of 4 quarters · filed 2024-08-12 |
| 2023-03-31 | -$20.63M 10-Q · filed 2024-05-06 | -$35.96M derived: sum of 2 quarters · filed 2024-05-06 | -$55.28M derived: sum of 3 quarters · filed 2024-05-06 | -$73.05M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | -$15.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | -$34.65M derived: sum of 2 quarters · filed 2024-03-11 | -$52.42M derived: sum of 3 quarters · filed 2024-03-11 | -$75.14M 10-K · filed 2024-03-11 |
| 2022-09-30 | -$19.32M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$37.10M derived: sum of 2 quarters · filed 2023-11-06 | -$59.81M 10-Q · filed 2023-11-06 | -$76.10M derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | -$17.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$40.49M 10-Q · filed 2023-08-10 | -$56.78M derived: sum of 3 quarters · filed 2023-08-10 | -$68.92M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$22.72M 10-Q · filed 2023-05-08 | -$39.00M derived: sum of 2 quarters · filed 2023-05-08 | -$51.14M derived: sum of 3 quarters · filed 2023-05-08 | -$67.36M derived: sum of 4 quarters · filed 2023-05-08 |
| 2021-12-31 | -$16.28M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$28.43M derived: sum of 2 quarters · filed 2023-03-16 | -$44.64M derived: sum of 3 quarters · filed 2023-03-16 | -$59.54M 10-K · filed 2023-03-16 |
| 2021-09-30 | -$12.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | -$28.36M derived: sum of 2 quarters · filed 2022-11-07 | -$43.26M 10-Q · filed 2022-11-07 | -$61.08M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | -$16.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$31.11M 10-Q · filed 2022-08-11 | -$48.94M derived: sum of 3 quarters · filed 2022-08-11 | -$58.52M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$14.90M 10-Q · filed 2022-05-09 | -$32.73M derived: sum of 2 quarters · filed 2022-05-09 | -$42.31M derived: sum of 3 quarters · filed 2022-05-09 | -$51.89M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | -$17.82M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$27.41M derived: sum of 2 quarters · filed 2022-03-21 | -$36.99M derived: sum of 3 quarters · filed 2022-03-21 | -$45.27M 10-K · filed 2022-03-21 |
| 2020-09-30 | -$9.58M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$19.16M derived: sum of 2 quarters · filed 2021-11-08 | -$27.44M 10-Q · filed 2021-11-08 | -$34.59M derived: sum of 4 quarters · filed 2022-03-21 |
| 2020-06-30 | -$9.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | -$17.86M 10-Q · filed 2021-08-10 | -$25.01M derived: sum of 3 quarters · filed 2022-03-21 | -$30.37M derived: sum of 4 quarters · filed 2022-03-21 |
| 2020-03-31 | -$8.28M 10-Q · filed 2021-05-06 | -$15.43M derived: sum of 2 quarters · filed 2022-03-21 | -$20.79M derived: sum of 3 quarters · filed 2022-03-21 | -$26.28M derived: sum of 4 quarters · filed 2022-03-21 |
| 2019-12-31 | -$7.15M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$12.51M derived: sum of 2 quarters · filed 2022-03-21 | -$18.00M derived: sum of 3 quarters · filed 2022-03-21 | -$23.53M 10-K · filed 2022-03-21 |
| 2019-09-30 | -$5.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | -$10.85M derived: sum of 2 quarters · filed 2020-11-05 | -$16.39M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | -$5.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$11.03M 10-Q · filed 2020-08-05 | ||
| 2019-03-31 | -$5.53M 10-Q · filed 2020-05-20 | |||
| 2018-12-31 | -$20.68M 10-K · filed 2021-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |